Lack of specific relevant know-how in regulatory science delays the development of new treatment strategies or limits the chances that promising innovations will reach patients. STARS aims to improve the direct regulatory impact of results obtained in medical research. 18 European countries are represented in the consortium through their national competent authorities, alongside academic and industry representatives, and associations with relevant experience.
More information: